{"id":7452,"date":"2025-03-12T08:40:00","date_gmt":"2025-03-12T07:40:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/"},"modified":"2025-03-12T08:40:00","modified_gmt":"2025-03-12T07:40:00","slug":"nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/","title":{"rendered":"Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa AB meddelar idag att den f\u00f6rsta patienten har doserats med 30 mg i den p\u00e5g\u00e5ende fas I-studien med NEX-22, bolagets enm\u00e5nadsformulering av liraglutid.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Den p\u00e5g\u00e5ende fas I-studien utv\u00e4rderar farmakokinetiken, s\u00e4kerheten och tolerabiliteten hos NEX-22, som anv\u00e4nder Nanexas patenterade PharmaShell\u00ae-teknologi f\u00f6r att m\u00f6jligg\u00f6ra en kontrollerad fris\u00e4ttning av l\u00e4kemedlet under en m\u00e5nad. Tidigare resultat fr\u00e5n studien har visat lovande s\u00e4kerhets- och farmakokinetikdata, vilket har banat v\u00e4g f\u00f6r denna doseskalering.<\/p>\n<p>&#034;Att dosera patienter med en 30 mg dos inom ramen f\u00f6r v\u00e5r f\u00f6rsta fas I-studie ger oss ett f\u00f6rspr\u00e5ng n\u00e4r vi g\u00e5r in i n\u00e4sta studie\u201d, s\u00e4ger David Westberg, vd f\u00f6r Nanexa. \u201dDet \u00e4r ytterligare ett steg fram\u00e5t i v\u00e5r str\u00e4van att utveckla innovativa och l\u00e5ngverkande behandlingar f\u00f6r patienter med typ 2-diabetes&#034;.<\/p>\n<p>Nanexa ser fram emot att dela med sig av ytterligare data och insikter fr\u00e5n studien n\u00e4r de blir tillg\u00e4ngliga.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/2316aefb-019a-42b1-943e-6f5895743263\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa AB meddelar idag att den f\u00f6rsta patienten har doserats med 30 mg i den p\u00e5g\u00e5ende fas I-studien med NEX-22, bolagets enm\u00e5nadsformulering av liraglutid.<\/p>\n","protected":false},"template":"","class_list":["post-7452","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att den f\u00f6rsta patienten har doserats med 30 mg i den p\u00e5g\u00e5ende fas I-studien med NEX-22, bolagets enm\u00e5nadsformulering av liraglutid.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\\\/\",\"name\":\"Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-03-12T07:40:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22 - Nanexa AB","og_description":"Nanexa AB meddelar idag att den f\u00f6rsta patienten har doserats med 30 mg i den p\u00e5g\u00e5ende fas I-studien med NEX-22, bolagets enm\u00e5nadsformulering av liraglutid.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/","name":"Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-03-12T07:40:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-forsta-patienten-i-dosgruppen-30-mg-i-fas-i-studien-med-nex-22\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa doserar f\u00f6rsta patienten i dosgruppen 30 mg i fas I-studien med NEX-22"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}